Scheele J - Search Results

1

Niazi F, Drevs J, Diergarten K, Dorn A, Maier A, Fiebig HH, Bruyns E, Scheele J. Niazi F, et al. Among authors: scheele j. Int J Oncol. 2009 May;34(5):1341-52. Int J Oncol. 2009. PMID: 19360346

2

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single-dose Auron Misheil therapy in healthy male subjects.

Scheele J, Diergarten K, Drevs J, Niazi FR. Scheele J, et al. J Clin Pharm Ther. 2013 Feb;38(1):3-11. doi: 10.1111/j.1365-2710.2009.01087.x. Epub 2009 Aug 14. J Clin Pharm Ther. 2013. PMID: 23281770 Clinical Trial.

3

A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life data.

Scheele J, Niazi F, Drevs J, Diergarten K, Toure P. Scheele J, et al. Oncol Rep. 2009 Oct;22(4):877-83. doi: 10.3892/or_00000512. Oncol Rep. 2009. PMID: 19724868 Clinical Trial.

4

Anti-tumor effects of AMT in the renal cell carcinoma model.

Caballero M, Scheele J, Zirrgiebel U, Esser N, Schächtele C, Soltau J, Rentschler J, Diergarten K, Drevs J. Caballero M, et al. Among authors: scheele j. Oncol Rep. 2010 Jan;23(1):205-10. Oncol Rep. 2010. PMID: 19956883

5

Effects of Auron-Misheil-Therapy in human in vitro skin models.

Scheele J, Mappes M, Dorn A, Niazi F. Scheele J, et al. J Dermatol. 2011 May;38(5):456-64. doi: 10.1111/j.1346-8138.2010.00994.x. Epub 2010 Nov 23. J Dermatol. 2011. PMID: 21352344

6

Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report.

Scheele JS, Harder J, Stankovic Z, Räpple D, Dorn A, Spangenberg HC, Blum HE. Scheele JS, et al. J Med Case Rep. 2011 Sep 24;5:478. doi: 10.1186/1752-1947-5-478. J Med Case Rep. 2011. PMID: 21943068 Free PMC article.

7

Rap1a deficiency modifies cytokine responses and MAPK-signaling in vitro and impairs the in vivo inflammatory response.

Dorn A, Zoellner A, Follo M, Martin S, Weber F, Marks R, Melchinger W, Zeiser R, Fisch P, Scheele JS. Dorn A, et al. Cell Immunol. 2012 Mar-Apr;276(1-2):187-95. doi: 10.1016/j.cellimm.2012.05.008. Epub 2012 May 23. Cell Immunol. 2012. PMID: 22695258

8

PBX1 is dispensable for neural commitment of RA-treated murine ES cells.

Jürgens AS, Kolanczyk M, Moebest DC, Zemojtel T, Lichtenauer U, Duchniewicz M, Gantert MP, Hecht J, Hattenhorst U, Burdach S, Dorn A, Kamps MP, Beuschlein F, Räpple D, Scheele JS. Jürgens AS, et al. Among authors: scheele js. In Vitro Cell Dev Biol Anim. 2009 May-Jun;45(5-6):252-63. doi: 10.1007/s11626-008-9162-5. Epub 2009 Jan 16. In Vitro Cell Dev Biol Anim. 2009. PMID: 19148706 Free PMC article.

9

The Spt-Ada-Gcn5-acetyltransferase complex interaction motif of E2a is essential for a subset of transcriptional and oncogenic properties of E2a-Pbx1.

Scheele JS, Kolanczyk M, Gantert M, Zemojtel T, Dorn A, Sykes DB, Möbest DC, Kamps MP, Räpple D. Scheele JS, et al. Leuk Lymphoma. 2009 May;50(5):816-28. doi: 10.1080/10428190902836107. Leuk Lymphoma. 2009. PMID: 19399691

10

Shear stress-mediated adhesion of acute myeloid leukemia and KG-1 cells to endothelial cells involves functional P-selectin.

Bistrian R, Dorn A, Möbest DC, Rüster B, Ludwig R, Scheele J, Seifried E, Martin H, Henschler R. Bistrian R, et al. Among authors: scheele j. Stem Cells Dev. 2009 Oct;18(8):1235-42. doi: 10.1089/scd.2008.0380. Stem Cells Dev. 2009. PMID: 19105599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238 results

Search Page